Uronic acid and probiotics

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmacology and medicine and represents application of composition, which contains probiotic bacteria of genus Lactobacillus or Bifidobacterium or both and from 25 to 100 wt % of uronic acid oligosaccharide, in which, at least, 50% of residues are selected from group consistsing of guluronic acid, mannuronic acid, galacturonic acid and glucuronic acid with DP from 2 to 250 on the basis of total mass of uronic acid in composition, for manufacturing nutritional composition for treatment and/prevention of infection with pathogen in person.

EFFECT: invention ensures synergic inhibiting of pathogens.

17 cl, 1 ex

 

The scope of the invention

This invention relates to compositions containing probiotics and prebiotic nutrients, which can be suitably used as baby food. The composition reduces the likelihood of infection.

The level of technology

Composition for babies are usually designed for playback of composite properties and protective effects of breast-milk man. One important step in the direction of this development is the inclusion of prebiotic fiber in the composition for children. Prebiotic fiber is also present in human breast milk and stimulates healthy bowel flora. Recently it was also found that oral intake of prebiotic fibres children encourages the development of a healthy immune system. More recent development is the inclusion for children of probiotic bacteria. Many studies confirm the beneficial effects of oral administration of probiotic bacteria.

Much research is currently being conducted to find optimal combinations of probiotic bacteria and prebiotic fiber (synbiotic compositions). WO 2004/089115 describes a composition comprising a strain ofLactobacillusand neoslavery oligosaccharide. WO 2004/0340 also describes the synbiotic composition.

The invention

In one aspect, the invention relates to a method for restoration of gastrointestinal flora, supporting the livelihoods of the gastrointestinal tract and prevents, for example, infection. Found that the uronic acid oligosaccharides and probiotic bacteria synergistically improve intestinal flora, especially in subjects with impaired intestinal flora or intestinal flora, which is in the process of development. Such an unbalanced intestinal flora is particularly common in children and patients who were subjected to, for example, surgery or treatment with antibiotics.

Oral intake of short-chain oligosaccharides uronic acid reduces the adhesion of pathogenic bacteria to the epithelium of the intestinal tract and, thereby, reduces the possibility of infection. Oral ingestion of these oligosaccharides are particularly useful for subjects who are susceptible to infections by pathogens, for example, for subjects with painful physiological condition or developing intestinal flora.

However, once the adhesion of pathogenic bacteria is reduced, pathogenic bacteria can stay and colonize the intestinal tract. Therefore, it is preferable that the reduced adhesion combined with restoration of intestinal flora and lowered into the possibility of colonization of the intestinal tract by pathogenic bacteria (i.e. increase of resistance to colonization). Resistance to colonization by pathogenic bacteria can be enhanced by the introduction of probiotic bacteria. Probiotic bacteria reduce nutrient availability, reducing, thereby, the rate of growth of pathogenic bacteria, and take in the gut designated adhesion of pathogenic bacteria.

In addition, it was found that probiotic bacteria, and uronic acid oligosaccharides stimulate systemic immune system.

Therefore, this invention relates to the composition of the oligosaccharide uronic acid and probiotic bacteria, which can be properly used to maintain and restore the activity of the gastrointestinal tract, can be used to prevent infection in subjects suffering from various diseases, when there is an imbalance gastrointestinal flora, and which is particularly applicable for entities with developing gastrointestinal flora such as children.

Therefore, in one aspect this invention relates to baby food that supports healthy development of the intestinal flora of the child.

In an additional aspect this invention relates to a composition which can be suitably used for the treatment and/or prevention infe the tion in patients Allergy, allergic rhinitis, food hypersensitivity, atopic dermatitis, eczema, asthma, diarrhoea, infectious or associated with antibiotics diarrhea, constipation, intestinal spasms, colic, acquired immunodeficiency syndrome, cancer, diabetes, cystic fibrosis, in patients undergoing surgery, patients undergoing anticancer therapy, and/or patients suffering from damage caused by heat, friction, electricity, radiation or chemicals.

This invention is further improved by combining uronic acid oligosaccharides and probiotic bacteria with prebiotic oligosaccharide. Prebiotic oligosaccharide enhances the combination of probiotic bacteria and uronic acid oligosaccharides, stimulating the growth of desirable good innate flora, especially Lactobacilli and Bifidobacteria, and helps the survival and provides nutrients for received probiotic bacteria. Prebiotic oligosaccharides, thus, specifically stimulate the prevalence of good intestinal bacteria.

A detailed description of the preferred options of the incarnation

This invention relates to a composition comprising probiotic bacteria and from 25 to 100 wt.% the uronic acid oligosaccharide with a DP between 2 and 250 on the basis of the total m the ssy uronic acid in the composition.

Probiotic material

This composition contains probiotic bacteria. Probiotic bacteria are presented in the form of mono - or mixed culture of live microorganisms which, when applied to man or animal, has a beneficial effect on the host by improving the properties of intestinal flora. Preferably, the composition contains from 102up to 1012more preferably from 104up to 1011most preferably from 107up to 5×1010, colony forming units (cfu) of probiotic bacteria per gram of uronic acid oligosaccharide with a DP between 2 and 250, preferably between DP 2 and 100. The composition preferably contains from 102up to 1013colony forming units (cfu) of probiotic bacteria per gram dry weight of the composition, preferably from 102up to 1012more preferably from 105up to 1010most preferably from 104up to 1×109cfu. Dosage of probiotic bacteria in this invention is preferably between 102and 1013more preferably from 105up to 1011most preferably from 108up to 5×1010colony forming units (cfu) per day.

Preferably, the composition comprises bacteria of the genusLactobacillusorBifidobacteriumor this composition comprises bacteria of the genus<> LactobacillusandBifidobacterium.Preferably the composition containsBifidobacterium,selected from the group consisting ofB.longum, B.breve, B.infantis, B.animalis, B.lactisandB.bifidum,most preferablyB.breve.Preferably the composition containsLactobacillus,selected from the group consisting ofL.casei, L.paracasei, L.rhamnosus, L.acidophilus, L.fermentumandL.plantarum.Most preferably the composition containsBifidobacterium breveand/orLactobacillus paracasei,because it was found that the growth of these bacteria is weakened in the intestines of children breastfed composition, compared with children breastfed.

Bifidobacterium breveare gram-positive anaerobic rod-shaped bacteria. DataB.brevepreferably have at least 95% identity to the sequence of the 16 S rRNA when compared with typical strain ofB.breveATCC 15700, more preferably at least 97% identity, as defined in Stackebrandt &Goebel, 1994, Int. J. Syst. Bacteriol. 44:846-849. The identity of nucleic acid sequences is preferably calculated for two nucleotide sequences, when they are optimally aligned using the programs GAP or BESTFIT using the values of the default settings. The values of the default parameters of GAP use with a penalty creation interval=50 (nucleotides)/8 (proteins) and penalty lengthening inter the Ala=3 (nucleotide)/2 (protein). For nucleotides used by the matrix to quantify the default is nwsgapdna (Henikoff &Henikoff, 1992, PNAS 89, 915-919). Obviously, when RNA sequences are referred to as essentially similar or have a specific degree of sequence identity with DNA sequences, thymine (T) in the DNA sequence is considered equal to uracil (U) in RNA sequences. Alignment of sequences and labels for percent sequence identity can be determined using computer programs such as the GCG Wisconsin Package, Version 10.3, available from Accelrys Inc., 9685 Scranton Road, San Diego, CA 92121-3752, USA or EMBOSSwin v. 2.10.0.

Bifidobacterium,used in this invention, it is preferable to give the signal when using the method of analysis with 5' nuclease, which are described in concurrently pending international patent application PCT/NL 2004/000748 and European patent application 05075486.0 the applicant. According to a preferred variant of this embodiment the composition contains at least one kind ofB.breve,selected from the group consisting ofB.breveBb-03 (Rhodia),B.breveM16-V (Morinaga),B.breveR0070 (Institute Rosell, Lallemand), DSM 20091 and LMG 11613. Most preferably,B.breveisB.breveM-16V (Morinaga).

In a preferred variant of this embodiment the composition containsLactobacillus paracasei.Preferably the data is a strain of L.paracaseihas at least 95, more preferably at least 97% identity to the 16S rRNA sequence, when compared to a typical strain ofL.paracaseiATCC 25032, as defined above.Lactobacillus,used in this invention, it is preferable to give the signal when using the method of analysis with 5' nuclease, which are described in concurrently pending European patent application of the applicant, application number 05075486.0. According to a preferred variant of this embodiment the composition comprises at leastL.paracasei,selected from the group consisting ofL.paracaseiF19 (Aria, Sweden),L.paracaseiLAFTI L26 (DSM Food Specialties, the Netherlands) andL.paracaseiCRL 431 (Chr. Hansen, Denmark), LMG 12165 and LMG 11407.

The uronic acid oligosaccharide

This composition contains between 25 and 100 wt.%, preferably between 50 and 100 wt.% the uronic acid oligosaccharide with a degree of polymerization (DP) from 2 to 250 based on total weight of uronic acid in the composition. Preferably the composition contains between 25 and 100 wt.%, preferably between 50 and 100 wt.% the uronic acid oligosaccharide with a degree of polymerization (DP) from 2 to 100, based on total weight of uronic acid in the composition. More preferably, the composition contains between 25 and 100 wt.% of the oligosaccharide galacturonic acid with a DP of 2 to 250 based on total weight of uronic acid in the composition, more preferably between 25 and 100 wt.% of the oligosaccharide galacturonic acid with a DP of 2 to 100, based on total weight of uronic acid in the composition, even more preferably between 25 and 100 wt.% of the oligosaccharide galacturonic acid with a DP between 2 and 50 based on total weight of uronic acid in the composition.

The term oligosaccharide uronic acid used in this invention refers to an oligosaccharide, where at least 50% of the residues selected from the group consisting of guluronic acid, mannurone acid, galacturonic acid and glucuronic acid. In a preferred variant embodiment of the uronic acid oligosaccharide contains at least 50% of the galacturonic acid on the basis of all residues of uronic acid oligosaccharide uronic acid. More preferably, the oligosaccharide uronic acid is hydrolyzed pectin, preferably polygalacturonic acid, even more preferably obtained by hydrolysis of pectin Apple, citrus and/or sugar beets.

In a preferred variant embodiment of the uronic acid oligosaccharides according to this invention contain between 25 and 100 wt.% galacturonic oligosaccharides with a DP between 2 and 100, based on the total mass of the galacturonic acid, more preferably between 50 and 100 wt.%, even more preferably between 75 and 100 wt.%. Preferably to the position contains between 25 and 100 wt.% galacturonic oligosaccharides with a DP between 2 and 50 based on the total mass of the galacturonic acid, more preferably between 50 and 100 wt.%, even more preferably between 75 and 100 wt.%.

Oligosaccharides the galacturonic acid preferably receive enzymatic digestion of pectin by pectinases, pectinases, andprecautions and/or a pectinase. The uronic acid oligosaccharide preferably can be obtained by enzymatic digestion of pectin by pectinases, pectinases, andprecautions and/or a pectinase.

The uronic acid oligosaccharide can be methoxymetopon and/or amitirova. The uronic acid oligosaccharide is preferably neoslavery in the upper division of the human gastrointestinal tract and are soluble in water.

In a preferred variant embodiment, at least one of the end links of hexose of uronic acid oligosaccharide has a double bond, which preferably is located between the position C4and C5end link hexose. The double bond provides effective protection against attachment of pathogenic bacteria to the epithelium. Preferably one of the end links of hexose contains a double bond. The double bond at an end link of hexose may be, for example, obtained by enzymatic hydrolysis of pectin by liati.

Preferably the uronic acid oligosaccharide has the structure I below, where the end hexose (left) site which preferably contains a double bond. Links hexose, other than end link (links) hexose are preferably units of uronic acid, preferably links the galacturonic acid. The group of carboxylic acids at these links can be free or partially esterified and preferably at least 10% methylated (see below).

Structure I: Polymeric acid oligosaccharide

where:

R is preferably selected from the group consisting of hydrogen, hydroxy or acid groups, preferably hydroxy; and

at least one radical selected from the group consisting of R2, R3, R4and R5represents the group N-acetylneuraminic acid, N-glycolylneuraminic acid, free or esterified carboxylic acid group, sulfuric acid or phosphoric acid, and the remaining R2, R3, R4and R5represent hydroxy and/or hydrogen. Preferably one radical selected from the group consisting of R2, R3, R4and R5represents the group N-acetylneuraminic acid, N-glycolylneuraminic acid, free or esterified carboxylic acid group, sulfuric acid or phosphoric acid, preferably in free or esterified carboxylic acid, and the others represent hydroxy and/elevatored. Even more preferably, one radical selected from the group consisting of R2, R3, R4and R5represents a free or esterified carboxylic acid, and the remaining R2, R3, R4and R5represent hydroxy and/or hydrogen; and

n means an integer and refers to the number of links of hexose (see also Degree of polymerization below), which can be any link in hexose. Accordingly, n means an integer number between 1-249, preferably between 1 and 99, more preferably between 1 and 49. Preferably the link (links) hexose is part of uronic acid.

Most preferably R, R2and R3represent hydroxy, R4is hydrogen, R5represents carboxylic acid, n is any number between 1 and 99, preferably between 1 and 50, most preferably between 1 and 10, and the link hexose is preferably a galacturonic acid.

More preferably, the uronic acid oligosaccharide has the structure according to figure 2.

Figure 2: Preferred end group hexuronic acid

where:

R is preferably selected from the group consisting of hydrogen, hydroxy or acid groups, preferably hydroxy (see above); and

at least one radical selected from the group Castiadas R 2, R3, R4and R5represents the group N-acetylneuraminic acid, N-glycolylneuraminic acid, free or esterified carboxylic acid group, sulfuric acid and phosphoric acid, and the remaining R2, R3, R4and R5represent hydroxy and/or hydrogen. Preferably one radical selected from the group consisting of R2, R3, R4and R5represents the group N-acetylneuraminic acid, N-glycolylneuraminic acid, free or esterified carboxylic acid group, sulfuric acid and phosphoric acid, and the remaining R2, R3, R4and R5represent hydroxy and/or hydrogen. Even more preferably, one radical selected from the group consisting of R2, R3, R4and R5represents a free or esterified carboxylic acid, and the remaining R2, R3, R4and R5represent hydroxy and/or hydrogen; and n means an integer and refers to the number of links of hexose (see also Degree of polymerization below), which can be any link in hexose. Accordingly, n means an integer number between 1-249 (preferably between 1 and 99, more preferably 1-49), representing the number of links of hexose, preferably which links uronic acids, even more preferably links and the galacturonic acid. The group of carboxylic acids at these links can be free or esterified and preferably are at least partially methylated.

Most preferably, R2and R3represent hydroxy, R4is hydrogen and R5represents a free or esterified carboxylic acid.

In an additional variant embodiment, a mixture of uronic acid oligosaccharides, which have different DP, and/or contains both unsaturated and saturated end link of hexose. Preferably at least 5%, more preferably at least 10%, even more preferably at least 25% of the limit hexuronate links are unsaturated hexuronic units of uronic acid oligosaccharide (see, e.g., figure 2). As each individual uronic acid oligosaccharide is preferably only contains one unsaturated end securenvoy link, preferably less than 50% of the limit hexuronate links are unsaturated geksanalem links (that contain a double bond).

The mixture of oligosaccharides uronic acid preferably contains between 2 and 50% unsaturated hexuronate links based on the total number of hexuronate units, preferably between 10 and 40%.

The uronic acid oligosaccharide can batterybattery. In one variant embodiment of the uronic acid oligosaccharides are characterized by a degree of methoxylation of about 20%, preferably about 50%, even more preferably about 70%. Used herein, the expression "degree of methoxylation" (also referred to as DE or "degree of esterification") is intended to indicate the extent to which the group is free karbonovoi acid contained in the circuit polygalacturonic acid, tarifitsirovana (e.g., methylation). In another variant embodiment of the uronic acid oligosaccharides have a degree of methylation of about 20%, preferably about 50%, even more preferably about 70%.

The concentration of uronic acid oligosaccharides

This composition is preferably a nutritional composition comprising a fat, digestible carbohydrates and protein. This nutritional composition preferably contains between 0.01 and 5 grams of uronic acid oligosaccharide with a DP of 2 to 250 per 100 grams of dry weight of the nutritional composition, more preferably between 0.05 and 2 grams per 100 grams dry weight. This nutritional composition preferably contains between 0.01 and 5 grams of the oligosaccharide galacturonic acid with a DP of 2 to 250, preferably DP 2-100) per 100 grams of dry weight of the nutritional composition, more preferably between 0.05 and 2 grams per 100 grams dry weight.

This with the persons preferably includes an introduction between 0.05 and 10 grams of uronic acid oligosaccharide with a DP of 2 to 100 per day, even more preferably between 0.1 and 5 grams of uronic acid oligosaccharides per day.

Prebiotic fiber

In addition to the oligosaccharide uronic acid and probiotic bacteria, the composition preferably contains a prebiotic fiber, which stimulates the growth of intestinal probiotic bacteria, especiallyBifidobacteriaand/orLactobacilli.Mainly, prebiotic fibers are at least 50% of the water-soluble oligosaccharides (L. Prosky et al, J. Assoc. Anal. Chem 71:1017-1023, 1988) with degree of polymerization (DP) of 2-100, which preferably do not contain uronic acids. Oligosaccharides deprived parts of uronic acids, referred to hereafter as "neoslavery oligosaccharide". Neoslavery oligosaccharide is not digested or only partially digested in the intestine by the action of acids or digestive enzymes present in the upper division of a human's digestive tract (small intestine and stomach) and are fermented by intestinal flora of man. For example, glucose, fructose, galactose, sucrose, lactose, maltose and maltodextrins are considered easy to digest.

Neoslavery the oligosaccharide is preferably a mixture of not digested sugars. It is a common practice, because the application neoslavery oligosaccharides, for example, with one DL is Noah chain is very common. Preferred examples of commercially available mixtures neoslavery oligosaccharides are inulin, fructooligosaccharide and galactooligosaccharide. When neoslavery the oligosaccharide is a mixture of saccharides, the average values of the corresponding parameters used for determining the present invention. For example, if the saccharide is A mixture of individual saccharides 25 wt.% Glu-Gal-Gal-Gal, 25 wt.% Glu-Gal-Gal and 50 wt.% Gal-Gal, the average composition of monosaccharides is a 85,4% Gal and 14.6% Glu. The average degree of polymerization (DP) is 2,75.

The degree of polymerization newsvideos oligosaccharide preferably less than 60, more preferably below 40, even more preferably below 20, most preferably below 10. The oligosaccharide preferably contains at least 60%, more preferably at least 95% of the links hexose selected from the group consisting of fructose, galactose and glucose.

Preferably, neoslavery oligosaccharide selected from the group consisting of such as: cellobiose (4-O-β-D-glyukopiranozil-D-glucose), allocstring ((4-O-β-D-glyukopiranozil)n-D-glucose), B-cyclodextrins (cyclic molecules of α-1-4-linked D-glucose; α-cyclodextrin-hexamer, β-cyclodextrin-heptamer and γ-cyclodextrin-octamer), neoslavery dextrin, gentiopicroside (mixture of β-1-6-linked glucose residues, not what the quiet 1-4), glucooligosaccharide (a mixture of α-D-glucose), isomaltooligosaccharide (linear α-1-6 linked glucose residues with some 1-4 linkages), isomaltose (6-O-α-D-glyukopiranozil-D-glucose); isomaltose (6-O-α-D-glyukopiranozil-(1-6)-α-D-glyukopiranozil-D-glucose), Panose (6-O-α-D-glyukopiranozil-(1-6)-α-D-glyukopiranozil-(1-4)-D-glucose), leucrose (5-O-α-D-glyukopiranozil-D-fructopyranose), palatinose or isomaltulose (6-O-α-D-glyukopiranozil-D-fructose), aanderaa (O-α-D-glyukopiranozil-(1-6)-O-α-D-glyukopiranozil-(1-2)-β-D-fructofuranoside), D-agarose, D-lyxo-hexulose, lactosucrose (O-β-D-galactopyranosyl-(1-4)-O-α-D-glyukopiranozil-(1-2)-β-D-fructofuranoside), α-galactooligosaccharide, including raffinose, stachyose and other soy oligosaccharides (O-α-D-galactopyranosyl-(1-6)-α-D-glyukopiranozil-β-D-fructofuranoside), β-galactooligosaccharide or transplantological (β-D-galactopyranosyl-(1-6)-[β-D-glyukopiranozil]n-(1-4)-α-D-glucose), lactulose (4-O-β-D-galactopyranosyl-D-fructose), 4'-galactopyranose (O-D-galactopyranosyl-(1-4)-O-β-D-glyukopiranozil-(1-4)-D-glucopyranose), synthetic galactooligosaccharide (neglectboth, isoglutamine, galactose, isolects I, II and III), fructans - type Levan (β-D-(2→6)-fructofuranosyl)n-α-D-glucopyranosid), fructans of the inulin type (β-D-((2→1)-fructofuranosyl)n-α-D-glucopyranosid), 1f-β-fructofuranosidase (β-D-((2→1)-proctoporus the ZIL) n-β-D-fructofuranoside), xylooligosaccharide (β-D-(1→4)-xylose)nlapidosa, lactosucrose, arabinopyranoside and mixtures thereof.

According to an additional preferred variant embodiment neoslavery oligosaccharide selected from the group consisting of fructans, fructo-oligosaccharides, neoslavery dextrins, galactooligosaccharides (including transplantological), xylooligosaccharides, soybean oligosaccharides, arabinopyranoside, glucooligosaccharides, mannooligosaccharides, focalisation and mixtures thereof.

Suitable newsweaver.ie oligosaccharides and methods for their preparation are additionally described in Laere KJM (Laere, KJM, Degradation of structurally different non-digestible oligosaccharides by intestinal bacteria: glycosylhydrolases of Bi. adolescentis. PhD thesis, June 2000, Wageningen Agricultural University, Wageningen, The Netherlands), the full contents of this publication are included in the description by reference.

The invention preferably relates to compositions with two different newsweaver.ie the oligosaccharides, for example, neoslavery the oligosaccharide A and neoslavery the oligosaccharide B, referred to hereafter as a saccharide and saccharide B, respectively. The A saccharide and saccharide B are preferably different sugars have different glycosidic bonds, the degree of polymerization and/or composition of monosaccharides.

Preferably at least 98% of all chains of monosaccharides with whom harida A and B are monosaccharides, selected from the group consisting of monosaccharides galactose (gal), fructose (fru) and glucose (glu). According to a preferred variant embodiment of the present invention, the percentage of at least one monosaccharide selected from the group consisting of glucose, fructose and galactose, in the saccharide A is at least 40% higher than the percentage of the same monosaccharide in the saccharide B, preferably at least 50%, more preferably at least 75%, even more preferably at least 90%. The increased diversity of monosaccharides encourages broader population of beneficial intestinal bacteria.

The percentage of the monosaccharide in the saccharide can be calculated by dividing the number of links of the respective monosaccharide (e.g. glucose) in the saccharide on the total number of monosaccharide units in the saccharide and multiplying by 100. When the saccharide is a mixture of saccharides, the contribution of each individual saccharide in a mixture of saccharides must be taken into account. The percentage sacharides mixture can be simply determined by complete hydrolysis of the mixture and determine the molar percentage of each monosaccharide.

Preferably the saccharide A is at least 40% galactose, more preferably at least 67% galactose, more preferably at least 75 mol.% galactose. P is edocfile saccharide B contains at least 30% fructose, more preferably at least 67% of fructose, even more preferably at least 80 wt.% fructose.

For example, in the case where the saccharide is A mixture of glu-(gal)n=2-7(n is, therefore, an integer selected from 2 to 7) with the average composition of monosaccharides 20% glucose and 80% galactose, and saccharide B is a mixture of glu-(fru)n=2-7and (fru)n=2-7with the average composition of monosaccharides 10% glucose and 90% fructose, the difference is (a) glucose 10%; (b) fructose 90% and (c) galactose 80%. In this example, and fructose, and galactose meet the criterion that the percentage of at least one monosaccharide selected from the group consisting of glucose, fructose and galactose, in the saccharide A is at least 40% higher than the percentage of the same monosaccharide in the saccharide B.

The degree of polymerization

The saccharides A and B have a degree of polymerization (DP) from 2 to 100. Preferably at least 80 wt.%, more preferably at least 95 wt.%, most preferably at least 98 wt.% the total mass of saccharide A and B have a degree of polymerization (DP) less than 60, more preferably below 40, most preferably below 20. Lower DP mainly reduces the viscosity and increases the ability to fermentation neoslavery saccharides. Preferably at least 50 wt.%, preferably at least 75 m is C.% of the total mass saccharides A and B are newsweaver.ie saccharides with DP 2-8. By using mixtures with high percentages of small saccharides can be further enhanced with the ability to fermentation and the effect of promoting the growth of lactic acid bacteria andBifidobacteria.

According to a preferred variant embodiment of the present invention DP saccharide A is at least 5 monosaccharide units lower than the degree of polymerization of the saccharide B, preferably at least 10, even more preferably at least 15. The inclusion of a saccharide with a high degree of polymerization reduces osmotic stress, which is favorable for baby food and also improves prebiotic stimulation of intestinal flora in the more distal parts of the colon.

Preferably, the saccharide has A DP 2-15, more preferably 2-8. Preferably the saccharide B is DP 8-100. The saccharides A and B with different DP can have the same or slightly different monosaccharide composition. When the saccharides A and B have different DP and similar monosaccharide composition, then the difference in the average DP between A saccharide and saccharide B is preferably at least 5, more preferably at least 10, even more preferably at least 15. Preferably, the saccharides A and B have different monosaccharide composition (see above) and different DP.

For example, if the saccharide is A mixture of glu-(fru)m=2-7and (fru)m=2-6with FCP is DNEVNOY DP 3,5 monosaccharide link and saccharide B is glu-(fru) m=12-100with average DP 25 monosaccharide units, then the difference in the average DP (25-3,5)=21,5.

In another preferred variant of embodiment of this invention the percentage of at least one glycosidic bonds of A saccharide on the basis of all glycosidic linkages of saccharide A is at least 40% higher than the percentage of the same glycosidic bonds in the saccharide B, preferably at least 50%, even more preferably at least 75%. The term "glycosidic bond"used in this invention, refers to the relationship C-O-C formed between the two rings of cyclic monosaccharides by removing water. Increased dissimilarity in glycosidic linkages encourages a broader range of beneficial bacteria.

Glycosidic bonds are different in that they covalently bind the carbon atoms in the monosaccharide units in different numbered positions and/or the fact that they form α or β linkages. Examples of different glycosidic linkages found in neoslavery the sugars are β(1,3), α(1,4), β(2,1), α(1,2) and β(1,4) linkages.

Preferably glycosidic bonds in A saccharide containing at least 40% β(1,4) and/or β(1,6) glycosidic linkages, more preferably at least 75%. Glycosidic bonds in the saccharide B preferably contain at least 40% β(2,1) glycosidic linkages, more preferably at the ore 75%.

The saccharide A is preferably a saccharide selected from the group consisting of β-galactooligosaccharides, α-galactooligosaccharides and galactanes. According to a more preferred variant embodiment the saccharide is A β-galactooligosaccharide, more preferably transplantological. Preferably the saccharide contains β-galactooligosaccharide with β(1,4) and/or β(1,6) glycosidic bonds and the terminal glucose. Transplantological, for example, commercially available under the trade name Vivinal®GOS (Borculo Domo Ingredients, Zwolle, Netherlands).

The saccharide B is preferably a saccharide selected from the group consisting of fructooligosaccharides and fructo-oligosaccharides. The terms fructooligosaccharide, polymaltose, polifruktan and fructan are used interchangeably and refer to polysaccharides containing β-linked chains of fructose, which are preferably linked β(2,1) and/or β(2,6) glycosidic bonds. Preferably, fructooligosaccharide end contains glucose with β(2,l) glycosidic bond. Preferably, fructooligosaccharide contains at least 7 β-linked chains of fructose. In an additional preferred variant of embodiment, the inulin is used as the saccharide B. Inulin is a type of fructooligosaccharide, where at least 75% of the glycosidic linkages represented by β(2,1) bonds. Usually inulin has an average on the inu chain from 8 to 60 monosaccharide units. Suitable fructooligosaccharide for use in the compositions of this invention are commercially available under the trade name Raftiline®HP (Orafti).

In an additional preferred variant of embodiment the saccharide B is fructooligosaccharide. Fructooligosaccharide is a saccharide containing β-linked chains of fructose, which are preferably linked β(2,1) and/or β(2,6) glycosidic bonds. Fructooligosaccharide preferably contains glucose with β(2,1) glycosidic bond to the reducing end. Preferably, fructooligosaccharide contains from 2 to 6 β-linked chains of fructose. A suitable source of fructooligosaccharide is Raftilose® (Orafti) or Actilight (Beghin-Meiji).

Concentration neoslavery oligosaccharides

The composition preferably contains at least 5 mg newsvideos of oligosaccharide per 100 grams of dry weight of the composition, more preferably at least 50 mg, even more preferably at least 0.1 g, most preferably at least 0,5, Preferably the composition does not contain more than 10 g newsvideos oligosaccharide 100 g dry weight of the composition, preferably not more than 2.0,

Newsweaver.ie oligosaccharides according to this invention is preferably administered in a daily dose of from 0.1 to 30 g, more preferably from 0.5 to 15 g, more p is edocfile from 3 to 10,

If the composition contains a saccharide and saccharide B, the mass ratio of saccharide A/saccharide B is preferably between 0.01 and 100, more preferably between 0.5 and 100, more preferably between 4 and 100, most preferably between 24 and 100. High mass ratio is particularly beneficial when the saccharide has A low DP and saccharide B has a relatively high DP. It provides the optimal balance between osmollnosti and ability to fermentation.

The A saccharide and saccharide B preferably comprise from 5 to 100 wt.% on the basis of the total mass neoslavery saccharides in the composition, more preferably from 50 to 100 wt.%.

Nutrient macronutrients

This composition when it is prepared as a nutritional composition preferably contains from 5 to 16 en% protein, 35 to 60 en% fat and 25 to 75 en% carbohydrates, preferably from 5 to 12.0 en% protein, from 39 to 50 en% fat and 40 to 55 en% carbohydrates (en% is short for energy percentage and represents the relative amount that each component contributes to the total caloric content of the product). Nutrient composition is particularly suitable for feeding infants, as it provides the child with essential nutrients.

This composition can also be added to breast milk. Products that are added in real time to gr is gnome milk, often refer to the amplifiers breast milk. Therefore, in an additional aspect this invention relates to a composition containing breast milk and this composition. In yet another additional aspect of this invention relates to a method for preparing a nutritional composition containing a mixture of breast milk and this composition.

Preferably, the composition contains from 5 to 20 en.% protein, more preferably from 8 to 12 en.%. Preferably the composition comprises a protein selected from the group consisting of casein, whey, skim milk, soy protein, pea protein, collagen, rice protein and/or corn protein. Preferably at least 25 wt.% total protein this composition presents hydrolyzed protein and/or free amino acid. The use of hydrolyzed protein and/or free amino acids reduces side effects such as allergies, which are particularly undesirable for children with suboptimal intestinal flora.

Preferably, the composition contains zinc (Zn). Zinc protects the intestinal barrier function in the presence of pathogens (Roselli et al, 2003, J Nutr. 133:4077) and plays an important role in proliferation of enterocytes. The composition preferably contains at least 10 mg of zinc on g dry weight of the composition, more preferably at least 30 μg, most is her preferably at least 50 μg Zn. Preferably, the composition contains less than 0.3 mg, more preferably not more than 0.2 mg of zinc on g dry weight of the composition. Preferably, the zinc is added to the composition in the form of zinc sulfate, zinc acetate, zinc chloride, zinc lactate, zinc citrate, zinc gluconate and/or zinc oxide.

This composition is preferably introduced in liquid form. The disruption of the chair (for example, a hard chair, insufficient stool, diarrhea) are a major problem in children with suboptimal intestinal flora. Therefore, this composition preferably has osmollnosti between 50 and 500 mOsm/kg, more preferably between 100 and 400 mOsm/kg With such osmollnosti this composition is particularly suitable for the treatment and/or prevention of diarrhea. Correct osmollnosti in combination with uronic acid oligosaccharides and probiotics reduces the time during which a normal chair is restored.

For some reason it is also important that the composition does not have a specific excess calories, providing, however, enough calories to supply the subject. Therefore, the liquid supply preferably has a specific caloric value between 0.1 and 2.5 kcal/ml, even more preferably the specific calorific value between 0.5 and 1.5 kcal/ml, most preferably between 0.6 and 0.9 kcal/ml of Optimalen the I specific caloric content also contributes to reducing the likelihood of diarrhea.

These compositions preferably contain mineral substances, trace elements and vitamins, choline, taurine, carnitine, monoset and/or mixtures thereof.

Applications

This composition is especially adapted for children. Therefore, this invention relates also to the use of this composition for obtaining nutritional composition for feeding children. Preferably, the children are aged 0-36 months, preferably age from 0 to 18 months.

The composition of this invention has been found particularly applicable as baby food. Also the composition is particularly suitable for the normalization of the populationBifidobacteriumand/orLactobacillusaccordingly, the distribution of the varieties of children breastfed in the gastrointestinal tract of children breastfed only partially breast milk or none at all, particularly those who are preterm infants, full-term infants, and children who are in the period of adaptation to solid food. Therefore, this invention relates to a method of feeding the child person, this method includes the introduction of the child in the song.

Thus, an additional aspect of this invention relates to a food product containing the composition, which determine the Jena above. In one variant embodiment the food product is baby food.

Intestinal flora has an important impact on disorders such as gastrointestinal disorders, immune disorders and/or endocrine disorders. Therefore, in an additional aspect, the invention relates to a method, the composition can be used in the manufacture of medicaments for use in the method of preventing and/or treating gastrointestinal disorders, immune disorders and/or endocrine disorders. In particular, Allergy, allergic rhinitis, hypersensitivity to food, atopic dermatitis, eczema, asthma, diarrhoea, infectious and associated with antibiotics diarrhea, intestinal inflammation, infection, constipation, intestinal spasms, colic, acquired immunodeficiency syndrome, cancer, cystic fibrosis and/or diabetes can be treated and/or prevented by this arrangement. In a preferred variant embodiment of the invention relates to a method of treatment and/or prevention of allergies and/or infection. In a preferred variant embodiment of the invention relates to a method of treatment and/or prevention of acquired immunodeficiency syndrome.

In an additional preferred variant of this embodiment the composition used in the method of treatment and/or the prevention of infection in patients Allergy, allergic rhinitis, food hypersensitivity, atopic dermatitis, eczema, asthma, diarrhoea, infectious or associated with antibiotics diarrhea, constipation, intestinal spasms, colic, acquired immunodeficiency syndrome, cancer, diabetes, cystic fibrosis, patients undergoing surgery, patients undergoing cancer treatment, and patients suffering from damage caused by heat, friction, electricity, radiation or chemicals. Reduced the probability of occurrence or the intensity of these diseases are the result of optimized intestinal flora, especially optimized population of the speciesBifidobacteriumand/or optimized population of the speciesLactobacillusand reduced adhesion of pathogenic bacteria.

In another variant embodiment, the invention relates to a method for prevention of vaginal infections, the specified method comprises topical application of the composition to be suitable for the introduction of the form.

EXAMPLES

Example 1: Composition of hydrolyzed pectin, prebiotic fiber and probiotic bacteria

Baby food containing 12.6 grams powder: 1.6 grams of protein, 3.6 grams of fat, 6.4 grams of easily digestible carbohydrates (mainly lactose), 0.8 grams neoslavery carbohydrates, of which 0.60 grams is rasgetentrydialparams, 0.07 grams of inulin (Raftilin HP, Orafti), 0.12 grams of hydrolyzed by liati pectin with an average degree of polymerization of 4 and 1×109cfuBifidobacteriumbreve M-16V (Moringa) and 1×109cfuLactobacillusparacasei LAFTIL26 (DSM Food Specialties, the Netherlands).

1. The use of a composition containing probiotic bacteria of the genus Lactobacillus or Bifidobacterium or both, and from 25 to 100 wt.% the uronic acid oligosaccharide, in which at least 50% of the residues selected from the group consisting of guluronic acid, mannurone acid, galacturonic and glucuronic acid with a DP of 2 to 250 based on total weight of uronic acid in the composition, for the manufacture of a nutritional composition for the treatment and/or prevention of infection by the pathogen in the subject.

2. The use according to claim 1, where the specified uronic acid oligosaccharide is hydrolyzed pectin.

3. The use according to claim 1 or 2, where the nutrient composition further comprises a prebiotic fiber, which stimulates the growth of intestinal probiotic bacteria selected from the group consisting of fructans, fructo-oligosaccharides, neoslavery dextrins, galactooligosaccharides (including transplantological), xylooligosaccharides, soybean oligosaccharides, arabinopyranoside, glucooligosaccharides, mannooligosaccharides, focalisation and mixtures thereof.

4. The use according to claim 1 or 2, where the specified subject who is a child or patient, which undergoes surgery or treatment with antibiotics.

5. Composition baby food suitable for feeding, containing
a. probiotic bacteria of the genus Lactobacillus or Bifidobacterium or both; and
b. from 25 to 100 wt.% the uronic acid oligosaccharide, in which at least 50% of the residues selected from the group consisting of guluronic acid, mannurone acid, galacturonic and glucuronic acid with a DP of 2 to 250 based on total weight of uronic acid in the composition.

6. Composition baby food according to claim 5, containing from 25 to 100 wt.% of the oligosaccharide galacturonic acid with a DP of 2 to 250 based on total weight of uronic acid in baby food.

7. Composition baby food according to claim 5 or 6, containing Bifidobacterium and optionally containing neoslavery oligosaccharide selected from the group consisting of fructans, fructo-oligosaccharides, neoslavery dextrins, galactooligosaccharides (including transplantological), xylooligosaccharides, soybean oligosaccharides, arabinopyranoside, glucooligosaccharides, mannooligosaccharides, focalisation and mixtures thereof.

8. Composition baby food according to claim 5 or 6, where the uronic acid oligosaccharide receive enzymatic digestion of pectin pectin-liati, pectin liati, andprecautions and/or a pectinase.

9. The composition of children is about the power supply according to claim 5 or 6, where the uronic acid oligosaccharide has the following structure:

where R is selected from the group consisting of hydrogen, hydroxy or acid groups, and at least one radical selected from the group consisting of R2, R3, R4and R5represents the group N-acetylneuraminic acid, N-glycolylneuraminic acid, free or esterified carboxylic acid group, sulfuric acid and/or a group of phosphoric acid, and the remaining R2, R3, R4and R5represent hydroxy and/or hydrogen, and n means an integer number 1-99.

10. Composition baby food according to claim 5 or 6, containing Bifidobacterium.

11. Composition baby food according to claim 5 or 6, containing Lactobacillus.

12. Composition baby food according to claim 5 or 6, containing Lactobacillus and Bifidobacterium.

13. Composition baby food according to claim 5 or 6, containing newsweaver.ie oligosaccharides, available from uronic acid.

14. The composition of breast milk fortifier, including
a. probiotic bacteria of the genus Lactobacillus or Bifidobacterium or both; and
b. from 25 to 100 wt.% the uronic acid oligosaccharide, in which at least 50% of the residues selected from the group consisting of guluronic acid, mannurone acid, galacturonic and glucuronic acid with a DP of 2 to 250 based on total weight of uronic acid.

15. The use to which notizie, defined in any of pp.5-14, for the manufacture of a nutritional composition for use in nutrition of children.

16. The use according to any one of claims 1 to 4, where this composition defined in any of pp.5-14.

17. The use according to claim 1, where the nutritional composition is intended for treating and/or preventing infection in a patient suffering from Allergy, allergic rhinitis, food hypersensitivity, atopic dermatitis, eczema, asthma, diarrhoea, infectious and associated with antibiotics diarrhea, constipation, intestinal spasms, colic, acquired immunodeficiency syndrome, cancer, diabetes, cystic fibrosis, patients undergoing surgery, patients undergoing cancer treatment and patients suffering from damage caused by heat, friction, electricity, radiation or chemicals.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed in pharmaceutical composition for external application for treatment or prevention of onichomycosis or prevention of hyperkeratotic tricophytosis, including: (i) luliconazole, represented by the following structural formula

(1)

and/or its salt; (ii) α-hydroxicarbonic acid and/or its salt and (iii) benzyl alcohol.

EFFECT: increase of penetration (absorption) of luliconazole through nail.

7 cl, 6 dwg, 15 tbl, 24 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine and chemical-pharmaceutical industry, in particular, to medication, containing as active substance 3,3'-diindolyl methane and carrier, which contains mixture of fish oil and, at least, one polysorbate.

EFFECT: elaboration of medication for treatment of human hyperplastic and inflammatory diseases.

6 cl, 7 dwg, 9 tbl, 15 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine, in particular to pharmacology. Composition contains fluconasole and auxiliary substances, as auxiliary substances it contains hypromellose, sodium chloride, benzalkonium chloride with the following ratio of ibgredients, wt %: fluconasole - 0.1 -2.0; hypromellose - 0.1-3.0; sodium chloride - 0.7-1.1; benzalkonium chloride - 0.005-0.02; water for injections - the remaining part to 100.

EFFECT: obtaining medication in form of solution based on fluconasole, which possesses antifungal activity in treatment of eye, ear and upper respiratory ways diseases, as well as ensuring prevention of said diseases in patients with impaired immune system.

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to process of crystallisation, obtaining and isolation of novel crystalline form of fusidic acid, to application of said processes in production of pharmaceutical composition or medication, and to application of said form of crystalline fusidic acid in treatment of bacterial infections.

EFFECT: obtaining pharmaceutical composition for treatment of bacterial infections.

11 cl, 10 ex, 1 tbl, 10 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, and is intended for conservative therapy of chronic ductoforitis, accompanied by syndrome of pathologic secretion. Method includes antibacterial and antiproliferative therapy. Antibacterial therapy is carried out locally by means of ductal lavage taking into account sensitivity of microflora to antibiotics. Ductal lavage is carried out with application of 0.3% fluoroquinolone or 2.5% cephalosporin. Daily per 7 procedures for each affected milk duct. After that, antiproliferative therapy by medication "Epigallat" in dose 500 mg 2 capsules 2 times per day in the morning and in the evening after meal. Day dose is 2000 mg. Course duration is from 3 to 6 months depending on treatment result.

EFFECT: invention makes it possible to increase efficiency of conservative treatment and reduce frequency of surgical interventions.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of pharmacology and medicine and represents rifampicin-based medication of prolonged action for treatment of resistant tuberculosis forms, which is different because it represents stable nanoparticles and contains rifampicic, biodegradable polymer of lactic acid or copolymer of lactic and glycolic acid, as well as surface active substance, cryoprotector, components in medication being in specified ratio in wt %.

EFFECT: invention ensures reduction of risk of toxic effects, prolonged action and reduction of intake factor in treatment.

6 cl, 3 ex, 1 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: claimed is application of: (a) solvating system which contains surface active substance, able to separate, remove or destruct in any other way, at least, part of biofilm, attached or adhered to a part of middle or internal ear, to the surface in nasal cavity or in sinus cavity, or to mouth or gullet tissue, and (b) polymer film-forming medical hermetic, able to form protective layer above the place, on which such biofilm was destroyed, and which possesses adhesion to natural tissues in the processed place and is resistant to separation or other destruction until natural decomposition or resorption of hermetic takes place, for manufacturing therapeutic system for treatment of infectious diseases of ear or throat, corresponding method of treatment and composition of said hermetic and anti-microbial preparation, which includes gallium-containing compound for application in the method. Demonstrated is 5.2-fold logarithmic reduction of the level of microbial contamination in vitro by cultures Staphylococcus aureus, Pseudomonas aeruginosa.

EFFECT: invention suggests efficiency of treatment by the claimed method of chronic otitis media with evaporation (COME), recurrent acute otitis media (RAOM), cholesteatoma, chronic rhinosinusitis.

71 cl, 4 dwg, 2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: claimed is application of: (a) solvating system which contains surface active substance, able to separate, remove or destruct in any other way, at least, part of biofilm, attached or adhered to a part of middle or internal ear, to the surface in nasal cavity or in sinus cavity, or to mouth or gullet tissue, and (b) polymer film-forming medical hermetic, able to form protective layer above the place, on which such biofilm was destroyed, and which possesses adhesion to natural tissues in the processed place and is resistant to separation or other destruction until natural decomposition or resorption of hermetic takes place, for manufacturing therapeutic system for treatment of infectious diseases of ear or throat, corresponding method of treatment and composition of said hermetic and anti-microbial preparation, which includes gallium-containing compound for application in the method. Demonstrated is 5.2-fold logarithmic reduction of the level of microbial contamination in vitro by cultures Staphylococcus aureus, Pseudomonas aeruginosa.

EFFECT: invention suggests efficiency of treatment by the claimed method of chronic otitis media with evaporation (COME), recurrent acute otitis media (RAOM), cholesteatoma, chronic rhinosinusitis.

71 cl, 4 dwg, 2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: composition for preventive and/or therapeutic treatment of respiratory pathologies and/or infections, or influenza, or for simultaneous improvement and/or regulation of organism's intestine function, includes mixture of bacterial strains, selected from: Bifidobacterium lactis LMG P-21384, Lactobacillus casei subspecies rhamnosus DSM 16605, Lactobacillus plantarum LMG P-21021 or Lactobacillus plantarum, LMG P-21020 or Lactobacillus plantarum LMG P-21022 or5 Lactobacillus plantarum LMG P-21023. Composition is applied for manufacturing medication for preventive and/or therapeutic treatment of respiratory pathologies and/or infections or for simultaneous improvement and/or regulation of organism's intestine function. Set for peroral introduction includes, at least, one composition of probiotic strains, at least one, pharmacologically active substance packed separately for introduction of said components.

EFFECT: efficiency of increasing systemic immune protection and immunity of mucous respiratory system membranes, improves or regulates organism's intestine function.

15 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to oxazolidinone derivatives covered by general graphic formula (I) and to their pharmaceutically acceptable salts. In formula (I) R1, R2, R3 and R4 are independently chosen from a group including -H and halogen; A is chosen from a group including R5 and R6 are independently chosen from a group including -H, -F, -CI, -Br, -OH, alkyl(C1-C6), haloalkyl(C1-C6), alkoxygroup(C1-C6); R7 is chosen from a group including -H, alkyl(C1-C6); either R7 and R5 or R6 taken together form a cycle of 2 carbon atoms and include 1 group chosen from O which in turn can be substituted by one substitute chosen from alkyl(C1-C6); R12 is chosen from a group including -H, -COR14, -CSR14, -COOR14; R14 is chosen from a group including alkyl (C1-C6), cycloalkyl(C3-C6), alkenyl(C2-C6), R16, R17 and R18 represent -H; R21 is chosen from a group including -H, alkyl(C1-C6); X is chosen from a group including O, S, and Y is chosen from a group including O, S, SO, SO2, and NR12; and optional substitutes of alkyl(C1-C6) groups can represent one or two groups chosen from the following: -OR21, -CN.

EFFECT: invention refers to methods for preparing the compounds of the invention, to application of oxazolidinone derivatives for preparing a drug for treating bacterial infections and to a pharmaceutical composition for treating bacterial infections, including a therapeutically effective amount of the compound of the invention.

36 cl, 10 tbl, 44 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, in particular, to field of pediatrics. Method includes application of medications. Additionally administered is probiotic Vitaflor in dose 1 ml, which contains 109 CFU Lactobacillus acidophilus, symbiotic strains "Д" No75 and "Д" No76, 3 times per day for 10 days.

EFFECT: method makes it possible to improve results of treating patients with pneumonia.

3 tbl, 2 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine and is intended for prevention of candidal lesions of digestive tract in treatment of patients with ulcerative colitis (UC), who obtain glucocorticosteroid (GCS) therapy. Therapy with glucocorticosteroids and 5-aminosalicilic acid preparations is carried out. Additionally administered is preparation "Vitaflor", intake per os in dose 1 capsule, covered with intestinally soluble coating, two times per day during entire treatment period.

EFFECT: invention makes it possible to suppress excessive growth of fungi of genus Candida in large intestine and prevent candidal lesion of mucous membrane of digestive tract in patients with UC, obtaining GCS therapy.

3 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: composition for preventive and/or therapeutic treatment of respiratory pathologies and/or infections, or influenza, or for simultaneous improvement and/or regulation of organism's intestine function, includes mixture of bacterial strains, selected from: Bifidobacterium lactis LMG P-21384, Lactobacillus casei subspecies rhamnosus DSM 16605, Lactobacillus plantarum LMG P-21021 or Lactobacillus plantarum, LMG P-21020 or Lactobacillus plantarum LMG P-21022 or5 Lactobacillus plantarum LMG P-21023. Composition is applied for manufacturing medication for preventive and/or therapeutic treatment of respiratory pathologies and/or infections or for simultaneous improvement and/or regulation of organism's intestine function. Set for peroral introduction includes, at least, one composition of probiotic strains, at least one, pharmacologically active substance packed separately for introduction of said components.

EFFECT: efficiency of increasing systemic immune protection and immunity of mucous respiratory system membranes, improves or regulates organism's intestine function.

15 cl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to orthopedics, and deals with treatment of dynamic equino-plano-valgus deformation of foot in children with infantile cerebral paralysis. For this purpose, if associated pathological motor stereotype of hip and shin muscles is detected carried out are injections of Disport medication, both into triceps muscle of shin, and into thigh adductors, shin flexors and peroneal muscles. Total medication dose constitutes 30 units per weight kilogram, but not more than 1000 units. 50% of dose are introduced in triceps muscle of shin, by 20% of dose - into thigh adductors and shin flexors and 10% - in peroneal muscles. Repeated injections are carried out according to the same scheme after 4-6 months.

EFFECT: method insures efficient treatment due to direct reduction of hypertone of muscles, which cause foot deformation, reduction of tibial synkinesis, which is basic mechanism of deformation pathogenesis, as well as evening-out of pathological pose, which assists progression of pathological foot setting.

9 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmacology, and represents application of at least one strain of probiotic bacteria Lactobacillus chosen from Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum 299v, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313, and Lactobacillus plantarum HEAL 99, DSM 15316, Lactobacillus paracasei 8700:2, DSM 13434 and Lactobacillus paracasei 02A, DSM13432 for preparing a pharmaceutical composition for treatment and/or prevention of multiple sclerosis (MS).

EFFECT: invention provides treatment and/or prevention of multiple sclerosis.

16 cl, 4 ex, 19 dwg

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely to pediatrics, and can be applied for treatment, prevention or reduction of systemic inflammatory in children at artificial feeding to level, which occurs at breast-feeding. For this purpose to child introduced is therapeutically efficient quantity of Lactobacillus rhamnosus GG (LGG) in combination with, at least, one long-chain polyunsaturated fatty acid (LCPUFA).

EFFECT: introduction of LGG and LCPUFA combination makes it possible to reduce systemic release of pro-inflammatory cytokines, chemokines and MPO considerably, conditioning efficiency of claimed therapy.

14 cl, 7 ex, 7 dwg

FIELD: medicine.

SUBSTANCE: Lactobacillus salivarius CNCM I 1794 and Lactobacillus paracasei CNCM I 1688 strains either separately or combined are applied for preparing a composition effective for immune system stimulation in the diseases associated with immune changes. The composition represents an oral composition, a dietary composition, a food composition or a nutritious composition containing salubrious additives.

EFFECT: invention enables certain immune system stimulation by making it stimulating more actively.

14 cl, 4 ex

FIELD: chemistry.

SUBSTANCE: Saccharomyces exiguous SJP6728AF1 (KCCM-10675P) strain and Saccharomyces exiguous S JP6729AF2 (KCCM-10677P) strain are used to produce bactericidal agents, insecticides, microbial preparations for fermentation of organic wastes, preparations for preventing appearance of or eliminating foul smell of organic wastes, for producing preservatives, feed additives and fermented food products.

EFFECT: invention increases efficiency of preparations for the given purposes.

10 cl, 15 tbl, 6 dwg, 18 ex

FIELD: medicine.

SUBSTANCE: strain Lactobacillus fermentum Ess-1,DSM17851 possesses probiotic properties and ability to suppress growth of yeast fingi Csandida and/or pathogenic bacteria, causing infection. Strain Lactobacillus fermentum Ess-1 is used for preparation of pharmaceutical composition for treatment and/or prevention of candidosis, vaginal candidosis, and bacterial infection, such as urinary tract infection. Invention also relates to pharmaceutical composition, to obtain which said strain is used, and hygienic product, which contains said bacterial strain. Method of treatment and/or prevention of bacterial infection, such as urinary tract infection, includes introduction to the subject of therapeutically efficient amount of strain Lactobacillus fermentum Ess-1.

EFFECT: invention ensures efficiency of strain application and treatment or prevention of candidosis and bacterial infections of urinary tract.

21 cl, 4 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: strain is obtained by insertion into genome of Escherichia coli, isolated from clinically healthy representative of canine family, of genes, determining synthesis of microcin C51, B-subunit of toxin, as well as vaccine version of elt-operon and A-subunit, enhancing immune response. Strain possesses expressed adhesion to mucous membrane of intestine of animals of canine family. Frozen dried culture of Escherichia coli EB387 represents probiotic medication for protection of animals of canine family against toxicoses, induced by cytotonic toxins of A1B5 type.

EFFECT: normalisation and stabilisation of qualitative and quantitative composition of gastrointestinal tract microflora in representatives of canine family.

2 cl, 3 ex

FIELD: food industry.

SUBSTANCE: invention relates to low-glycemic affordable carbohydrate composition. Carbohydrate composition in compliance with invention contains the following components: (i) 5-60 wt %, one or more monosaccharides, selected from monosaccharides that differ from glucose and fructose, in particular, galactose, ribose and mannose; (ii) 10-75 wt % oligosaccharides, having length of 2-20 anhydromonose units, at least half of which represents anhydroglucose remains bound in alpha-1-position with 1-, 3-, 5- or 6 positions of another anhydromonose unit, besides, component (ii) contains 10-60 wt % of one or more oligosaccharides selected from trehalulose, palatinose, turanose and leucrose; (iii) 0-75 wt %, other affordable carbohydrates. Invention also relates to food composition, containing low-glycemic carbohydrate composition and proteins and/or lipids, besides, carbohydrate composition makes 35-70 en.% of food composition. Food composition is used to treat diabetes, obesity, resistance to insulin, or for postprandial reaction to glucose.

EFFECT: carbohydrate composition makes it possible to maintain low level of glucose in blood and tissues after consumption for a long period of time and does not result in undesirable high concentrations of glucose in blood in people, who became resistant to insulin.

12 cl, 1 ex

Up!